Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105975 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 398
- Enrollment target
NCT01105975: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01105975 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 398 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (199% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01105975, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 398 participants
- Enrollment target
Study Summary
The primary purpose of your participation in this study is to help answer the following research question(s) * Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile more than statins alone. * Whether LY2484595 alone improves blood fats profile compared to sugar pills. * Whether LY2484595 interferes with break down or functioning of statins. * Whether LY2484595 has any side effects that would not support testing it in future studies.
Primary Outcome
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Interventions
- DRUG Rosuvastatin
- DRUG Simvastatin
- DRUG Atorvastatin
- DRUG LY2484595
- DRUG Placebo for LY2484595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT01105975 record still lists
NCT01105975 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (199% higher).
The record links to 0 conditions, and to 5 interventions - of which Rosuvastatin is the first listed.
NCT01105975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01105975 about?
NCT01105975 is a clinical study titled "A Study of LY2484595 in Patients With High LDL-C or Low HDL-C". The primary purpose of your participation in this study is to help answer the following research question(s) * Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile...
What is the current status of trial NCT01105975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 398 participants. The study started on 2010-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01105975?
The interventions under investigation include: Rosuvastatin (DRUG), Simvastatin (DRUG), Atorvastatin (DRUG), LY2484595 (DRUG), Placebo for LY2484595 (DRUG).
Who is sponsoring clinical trial NCT01105975?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01105975's enrollment target sits among peer trials
398 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia